Aim To investigate the prevalence of familial hypercholesterolemia in patients with acute coronary syndrome (ACS). Methods The study included fifteen patients with first or repeated ACS and treated/nontreated dyslipidaemia admitted to the Department of Cardiovascular Diseases of Clinical Hospital Centre Osijek between 1 January 2020 and 1 January 2021. The cut-off value of low-density lipoprotein (LDL)-C was 4.5mmol/L as a possible cut-off value for familial hypercholesterolemia presence. Data were collected from medical history and during patient’s follow-up. Results Included patients that fulfilled criteria were predominantly male – 14 (93%), mean age 61 years. The median level of LDL cholesterol at admission because of ACS was 5.14 mmol/L, whereas the follow-up level after one year was 2.27 mmol/L (p=0.001). At first follow-up, 7 (46%) patients were treated with atorvastatin 80 mg or rosuvastatin 40 mg, 3 (20%) atorvastatin 80mg + ezetimibe 10mg, 2 (13%) with rosuvastatin 40 mg+ ezetimibe 10 mg, other patients were treated with a lower dose of statin or ezetimibe. According to LDL-C profile and by calculating the Dutch Lipid Clinic Network Score, one (of 15) patient was categorized as having definite familial hypercholesterolemia and two (of 15) as having probable familial hypercholesterolemia leading to the use of triple hypolipidemic therapy (statin+ezetimibe+PCSK9 inhibitor) in 2 (13%) patients (one female and one male). Conclusion LDL-C level of 4.5 mmol/L and higher represents an indication for screening for familial hypercholesterolemia in patients with ACS. The prevalence of familial hypercholesterolemia in ACS, estimated by the Dutch Lipid Clinic Network Score, could be higher than previously reported.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. ESC scientific document. 2019;41:111–88.
2.
Pirillo A, Catapano AL, Norata GD. Monoclonal antibodies in the management of familial hypercholesterolemia: Focus on PCSK9 and ANGPTL3 inhibitors. Curr Atheroscler Rep. 2021;23(79).
3.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Fourier steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
4.
Dyrbuś K, Gąsior M, Desperak P, Osadnik T, Nowak J, Banach M. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019;288:33–41.
5.
LDL-C calculator – Lipid Tools. 2023.
6.
Lipid Tools. 2023.
7.
Šálek T, Soška V, Budina M, Vecka M, Šálková V, Vrablík M. Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia. Biochem Medica. 2023;33(030705).
8.
Ide V, Cock D, Pazmino S, Vangoitsenhoven R, Schueren B, Mertens A. A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic. Acta Cardiol. 2023;1–10.
9.
Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D’Erasmo L, et al. Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: A retrospective cohort study based on the AIFA monitoring registries. J Am Heart Assoc. 2023;026550.
10.
Tada H, Kaneko H, Suzuki Y, Okada A, Takeda N, Fujiu K, et al. Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Eur J Clin Invest. 2023;14119.
11.
Probir i rano otkrivanje porodične hiperkolesterolemije.
12.
Pećin I, Šućur N, Reiner Ž. Porodična hiperkolesterolemija - mislimo li dovoljno o ovoj teškoj bolesti (Familial hypercholesterolemia - do we think enough about this severe disease. Croatian] Liječnički Vjesn. 2013;135:0–0.
13.
Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71:1–7.
14.
McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019;8:e013225.
15.
Corral P, Aguilar Salinas CA, Matta MG, Zago V, Schreier L. Stratification in heterozygous familial hypercholesterolemia: imaging, biomarkers, and genetic testing. Curr Atheroscler Rep. 2023;
16.
Mohamed F, Mansfield B, Raal FJ. Targeting PCSK9 and beyond for the management of low-density lipoprotein cholesterol. J Clin Med. 2023;12(5082).
17.
Cui Y, Li S, Zhang F, Song J, Lee C, Wu M, et al. Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction. Clin Cardiol. 2019;42:385–90.
18.
Casula M, Olmastroni E, Pirillo A, Catapano AL. Members of the LIPIGEN steering commettee, Principal investigators: Coordinator center; Participant Centers; Participant Laboratories. In: COLLABORATORS; STUDY CENTRAL LABORATORY AND ANALYSIS GROUP Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. 2018. p. 413–8.
19.
Li S, Zhang Y, Zhu CG, Guo YL, Wu NQ, Gao Y, et al. Identification of familial hypercholesterolemia in patients with myocardial infarction: a Chinese cohort study. J Clin Lipidol. 2016;10:1344–52.
20.
Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, et al. Familial hypercholesterolemia among young adults with myocardial infarction. J Am Coll Cardiol. 2019;73:2439–50.
21.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90.
22.
Jug J, Juraga V, Jelavić I. Adherencija i propisivanje statina u primarnoj prevenciji unutar primarne zdravstvene zaštite (Adherence and prescription of statin therapy in primary prevention in primary care unit. Croatian] Liječnički Vjesn. 2021;143:90–4.
23.
Pintarić H, Knezović Florijan M, Bridges I, Steiner R, Zaputović L, Miličić D. Management of hyperlipidemia in very high and extreme risk patients in Croatia: an observational study of treatment patterns and lipid control. Acta Clin Croat. 2020;59:641–9.
24.
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75:2553–66.
25.
Romero-Jiménez MJ, Mansilla-Rodríguez ME, Gutiérrez-Cortizo EN. Predictors of cardiovascular risk in familial hypercholesterolemia. Curr Opin Lipidol. 2023;34:272–7.
26.
Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 2018;19:E3426.
27.
Rogozik J, Główczyńska R, Grabowski M. Genetic backgrounds and diagnosis of familial hypercholesterolemia. Clin Genet. 2023;
28.
Panel P, J G, RA H, J B, J B, A C, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. 2014.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
